Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer F Hoy

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Ebiomedicine|July 30, 2017
Immunometabolic and Lipidomic Markers Associated With the Frailty Index and Quality of Life in Aging HIV+ Men on Antiretroviral TherapyHui-Ling Yeoh, Allen C Cheng, Catherine L Cherry, et al.
AIDS Care|March 30, 2023
Practical management of complexity in older people with HIV: approaching an international consensusTristan J Barber, Brenda Crabtree, Claudia P Cortes, et al.
AIDS (London, England)|June 18, 2009
Continuous antiretroviral therapy decreases bone mineral densityBirgit Grund, Grace Peng, Cynthia L Gibert, et al.
Cancer|June 16, 2004
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patientsMark E Newell, Jennifer F Hoy, Stephen G Cooper, et al.
Sexual Health|December 5, 2016
Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance systemAnna B Pierce, Carol El-Hayek, Damien McCarthy, et al.
AIDS (London, England)|May 31, 2018
Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individualsEmily L Woolnough, Jennifer F Hoy, Allen C Cheng, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
Journal of Neurovirology|August 15, 2013
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effectBirgit Grund, Edwina J Wright, Bruce J Brew, et al.
The Medical Journal of Australia|November 24, 2011
Outcomes from the first assisted reproduction program for HIV-serodiscordant couples in AustraliaMichelle L Giles, Shlomi Barak, Gordon Baker, et al.
Journal of Electrocardiology|January 11, 2014
Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] StudyFarah Z Dawood, Mollie P Roediger, Greg Grandits, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Ebiomedicine|July 30, 2017
Immunometabolic and Lipidomic Markers Associated With the Frailty Index and Quality of Life in Aging HIV+ Men on Antiretroviral TherapyHui-Ling Yeoh, Allen C Cheng, Catherine L Cherry, et al.
AIDS Care|March 30, 2023
Practical management of complexity in older people with HIV: approaching an international consensusTristan J Barber, Brenda Crabtree, Claudia P Cortes, et al.
AIDS (London, England)|June 18, 2009
Continuous antiretroviral therapy decreases bone mineral densityBirgit Grund, Grace Peng, Cynthia L Gibert, et al.
Cancer|June 16, 2004
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patientsMark E Newell, Jennifer F Hoy, Stephen G Cooper, et al.
Sexual Health|December 5, 2016
Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance systemAnna B Pierce, Carol El-Hayek, Damien McCarthy, et al.
AIDS (London, England)|May 31, 2018
Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individualsEmily L Woolnough, Jennifer F Hoy, Allen C Cheng, et al.
Plos One|November 9, 2013
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapyAllison Martin, Cecilia L Moore, Patrick W G Mallon, et al.
Journal of Neurovirology|August 15, 2013
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effectBirgit Grund, Edwina J Wright, Bruce J Brew, et al.
The Medical Journal of Australia|November 24, 2011
Outcomes from the first assisted reproduction program for HIV-serodiscordant couples in AustraliaMichelle L Giles, Shlomi Barak, Gordon Baker, et al.
Journal of Electrocardiology|January 11, 2014
Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] StudyFarah Z Dawood, Mollie P Roediger, Greg Grandits, et al.
Pageof 10